Conference item icon

Conference item

SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer

Abstract:
Chemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/annonc/mdx262.026

Authors


More by this author
Department:
Oxford, MSD, NDORMS, CSM
More by this author
Department:
Oxford, MSD, Oncology
More by this author
Department:
Oxford, MSD, NDORMS, CSM
More by this author
Department:
Oxford, MSD, Oncology
Expand authors...
Publisher:
Oxford University Press Publisher's website
Publication date:
2017-06-26
Acceptance date:
2017-04-24
DOI:
Pubs id:
pubs:691019
URN:
uri:06e219dc-1d45-496b-a853-bc9aff80b62f
UUID:
uuid:06e219dc-1d45-496b-a853-bc9aff80b62f
Local pid:
pubs:691019

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP